Frontiers in Medicine (Dec 2023)

Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease

  • Antonio Vitale,
  • Antonio Vitale,
  • Valeria Caggiano,
  • Valeria Caggiano,
  • Petros P. Sfikakis,
  • Lorenzo Dagna,
  • Lorenzo Dagna,
  • Giuseppe Lopalco,
  • Gaafar Ragab,
  • Gaafar Ragab,
  • Francesco La Torre,
  • Ibrahim A. Almaghlouth,
  • Ibrahim A. Almaghlouth,
  • Maria Cristina Maggio,
  • Jurgen Sota,
  • Jurgen Sota,
  • Abdurrahman Tufan,
  • Andrea Hinojosa-Azaola,
  • Florenzo Iannone,
  • Roberta Loconte,
  • Katerina Laskari,
  • Haner Direskeneli,
  • Piero Ruscitti,
  • Maria Morrone,
  • Henrique A. Mayrink Giardini,
  • Alexandros Panagiotopoulos,
  • Ilenia Di Cola,
  • Eduardo Martín-Nares,
  • Sara Monti,
  • Sara Monti,
  • Ludovico De Stefano,
  • Ludovico De Stefano,
  • Rıza Can Kardas,
  • Rahime Duran,
  • Corrado Campochiaro,
  • Corrado Campochiaro,
  • Alessandro Tomelleri,
  • Alessandro Tomelleri,
  • Abdulaziz Mohammed Alabdulkareem,
  • Carla Gaggiano,
  • Carla Gaggiano,
  • Maria Tarsia,
  • Maria Tarsia,
  • Elena Bartoloni,
  • Mery Romeo,
  • Mohamed A. Hussein,
  • Ahmed Hatem Laymouna,
  • Isabele Parente de Brito Antonelli,
  • Marilia Ambiel Dagostin,
  • Lampros Fotis,
  • Sara Bindoli,
  • Luca Navarini,
  • Luca Navarini,
  • Fatma Alibaz-Oner,
  • Gizem Sevik,
  • Micol Frassi,
  • Francesco Ciccia,
  • Daniela Iacono,
  • Francesca Crisafulli,
  • Piero Portincasa,
  • Nour Jaber,
  • Perla Ayumi Kawakami-Campos,
  • Ewa Wiesik-Szewczyk,
  • Annamaria Iagnocco,
  • Gabriele Simonini,
  • Paolo Sfriso,
  • Alberto Balistreri,
  • Roberto Giacomelli,
  • Roberto Giacomelli,
  • Giovanni Conti,
  • Bruno Frediani,
  • Bruno Frediani,
  • Claudia Fabiani,
  • Claudia Fabiani,
  • Luca Cantarini,
  • Luca Cantarini

DOI
https://doi.org/10.3389/fmed.2023.1256243
Journal volume & issue
Vol. 10

Abstract

Read online

IntroductionThe effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.MethodsPatients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still’s disease. Seventy-seven (51 females and 26 males) patients with Still’s disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.ResultsNo statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.ConclusionCanakinumab has proved to be effective in patients with Still’s disease, regardless of its line of biologic treatment.

Keywords